Jeanine “Nini” Martin Joins the Qmetis Medical Advisory Board

Jeanine “Nini” Martin Joins the Qmetis Medical Advisory Board

March 18, 2018 

New York, New York – Qmetis Inc., a healthcare technology company that builds clinical decision-support tools for doctors, nurses, and hospitals in the areas of trauma, stroke, sepsis and spinal cord injury, announced today that Jeanine “Nini” Martin had joined its medical advisory board.

Ms. Martin is the Global Chief Growth Officer for C3 Global Biosciences, a member of the senior management group of Athletes for Care, the past President of WITI, Women in Technology International, the past President of the Association of Information Technology Professionals and former Advisory Board Member to the American Society of Clinical Oncology (ASCO). Ms. Martin is a graduate of the University of California Santa Barbara prior to continuing her studies in clinical informatics at the Johns Hopkins University School of Medicine. She is the former director of the Women’s NFL and a standout athlete herself competing in tennis at an Olympic level.

“If you look at most of the major healthcare issues facing us today; long-term care, overall cost and affordability, caring for an aging population, veterans’ care, concussion, opioid addiction, Nini is involved in almost all of them, and involved thoughtfully and compassionately. Her interest in this generation of patients, and the next, is inspiring. Qmetis is lucky to have her helping us achieve our goals” said Jack Fitzgibbons, Qmetis’s Chief Operating Officer.

About Qmetis 

Qmetis, founded in 2012, builds and delivers evidence-based decision-support tools that meet its mission of helping doctors, nurses, and hospitals achieve the highest levels of quality possible for each case, each shift, for dozens of illnesses and conditions worldwide. For more on Qmetis, visit qmetis.com.

Press Contact: Brian Simmons Marketing Manager simmons@qmetis.com

Qmetis
info@qmetis.com
No Comments

Post A Comment

Want to see how Qmetis can help you reduce costs and improve outcomes?